Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors

Abstract Background Rituximab‐based combinations are the standard of care in diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL). Despite being on market for over 20 years, some of the adverse effects associated with the use of rituximab are not well known. Drug‐induced interstitial p...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Elina Kaprio, Roosa Prusila, Susanna Tokola, Milla E. L. Kuusisto, Esa Jantunen, Hanne Kuitunen, Taina Turpeenniemi‐Hujanen, Outi Kuittinen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-01-01
coleção:	Cancer Medicine
Assuntos:	diffuse large B‐cell lymphoma drug‐induced pneumonitis follicular lymphoma granulocyte colony‐stimulating factors
Acesso em linha:	https://doi.org/10.1002/cam4.6898
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!